Medios AG
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MEDOF research report →
Companywww.medios.ag
Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases.
- CEO
- Thomas Meier
- IPO
- 2021
- Employees
- 472
- HQ
- Berlin, DE
Price Chart
Valuation
- Market Cap
- $1.28B
- P/E
- 23.17
- P/S
- 0.15
- P/B
- 0.62
- EV/EBITDA
- 5.29
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 6.92%
- Op Margin
- 2.06%
- Net Margin
- 0.66%
- ROE
- 2.69%
- ROIC
- 2.99%
Growth & Income
- Revenue
- $1.88B · 5.51%
- Net Income
- $12.55M · -33.29%
- EPS
- $0.51 · -35.44%
- Op Income
- $31.66M
- FCF YoY
- 344.78%
Performance & Tape
- 52W High
- $50.00
- 52W Low
- $13.64
- 50D MA
- $50.00
- 200D MA
- $50.00
- Beta
- 1.31
- Avg Volume
- 1.10K
Get TickerSpark's AI analysis on MEDOF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our MEDOF Coverage
We haven't published any research on MEDOF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MEDOF Report →